GlaxoSmithKline [GLAXO] vs Marksans Pharma [MARKSANS] Detailed Stock Comparison

GlaxoSmithKline

NSE
Loading...

Marksans Pharma

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: GlaxoSmithKline wins in 14 metrics, Marksans Pharma wins in 6 metrics, with 0 ties. GlaxoSmithKline appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricGlaxoSmithKlineMarksans PharmaBetter
P/E Ratio (TTM)47.3921.35Marksans Pharma
Price-to-Book Ratio23.093.03Marksans Pharma
Debt-to-Equity Ratio0.5112.93GlaxoSmithKline
PEG Ratio3.81-0.62Marksans Pharma
EV/EBITDA36.2815.21Marksans Pharma
Profit Margin (TTM)25.41%13.20%GlaxoSmithKline
Operating Margin (TTM)29.27%12.42%GlaxoSmithKline
EBITDA Margin (TTM)29.27%12.42%GlaxoSmithKline
Return on Equity47.54%15.29%GlaxoSmithKline
Return on Assets (TTM)22.58%11.75%GlaxoSmithKline
Free Cash Flow (TTM)$12.65B$337.45MGlaxoSmithKline
Dividend Yield1.65%0.62%GlaxoSmithKline
1-Year Return-1.52%-42.49%GlaxoSmithKline
Price-to-Sales Ratio (TTM)12.052.82Marksans Pharma
Enterprise Value$425.69B$71.76BGlaxoSmithKline
EV/Revenue Ratio11.382.71Marksans Pharma
Gross Profit Margin (TTM)64.27%57.77%GlaxoSmithKline
Revenue per Share (TTM)$221$59GlaxoSmithKline
Earnings per Share (Diluted)$56.12$7.73GlaxoSmithKline
Beta (Stock Volatility)0.041.23GlaxoSmithKline
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

GlaxoSmithKline vs Marksans Pharma Stock Performance Analysis

Loading Price Chart...

GlaxoSmithKline
Marksans Pharma
GlaxoSmithKline Stock Overview | Marksans Pharma Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
GlaxoSmithKline1.62%-1.79%-3.96%-19.57%-3.58%20.84%
Marksans Pharma0.14%-2.00%-0.42%-35.52%-24.91%-45.29%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
GlaxoSmithKline-1.52%93.34%80.13%-18.74%17.61%513.98%
Marksans Pharma-42.49%252.74%211.24%57.76%4,066.75%553.61%

News Based Sentiment: GlaxoSmithKline vs Marksans Pharma

GlaxoSmithKline

News based Sentiment: MIXED

September 2025 brought both positive earnings results and concerning signals for GSK Pharma. While profitability improved, the stock faced a decline and regulatory hurdles persist. The planned oncology launches offer potential, but the overall picture is complex, making it a mixed month for investors.

View GlaxoSmithKline News Sentiment Analysis

Marksans Pharma

News based Sentiment: NEGATIVE

September proved to be a difficult month for Marksans Pharma, with disappointing financial results and a significant decline in stock price overshadowing positive developments like regulatory approvals. The shift in institutional investment patterns and insider selling further contribute to a negative outlook, making this a crucial period for the company to demonstrate a turnaround strategy.

View Marksans Pharma News Sentiment Analysis

Performance & Financial Health Analysis: GlaxoSmithKline vs Marksans Pharma

MetricGLAXOMARKSANS
Market Information
Market Cap i₹458.57B₹77.07B
Market Cap CategoryLarge capMid cap
10 Day Avg. Volume i97,6021,010,590
90 Day Avg. Volume i94,9031,079,284
Last Close₹2,741.00₹166.90
52 Week Range₹1,921.00 - ₹3,515.70₹162.51 - ₹358.70
% from 52W High-22.04%-53.47%
All-Time High₹3,872.00 (Mar 28, 2016)₹358.70 (Dec 02, 2024)
% from All-Time High-29.21%-53.47%
Growth Metrics
Quarterly Revenue Growth-0.01%0.05%
Quarterly Earnings Growth0.12%-0.34%
Financial Health
Profit Margin (TTM) i0.25%0.13%
Operating Margin (TTM) i0.29%0.12%
Return on Equity (TTM) i0.48%0.15%
Debt to Equity (MRQ) i0.5112.93
Cash & Liquidity
Book Value per Share (MRQ)₹115.19₹54.44
Cash per Share (MRQ)₹147.46₹15.58
Operating Cash Flow (TTM) i₹12.73B₹2.42B
Levered Free Cash Flow (TTM) i₹9.28B₹3.81B
Dividends
Last 12-Month Dividend Yield i1.65%0.62%
Last 12-Month Dividend i₹54.00₹1.40

Valuation & Enterprise Metrics Analysis: GlaxoSmithKline vs Marksans Pharma

MetricGLAXOMARKSANS
Price Ratios
P/E Ratio (TTM) i47.3921.35
Forward P/E i45.9413.83
PEG Ratio i3.81-0.62
Price to Sales (TTM) i12.052.82
Price to Book (MRQ) i23.093.03
Market Capitalization
Market Capitalization i₹458.57B₹77.07B
Enterprise Value i₹425.69B₹71.76B
Enterprise Value Metrics
Enterprise to Revenue i11.382.71
Enterprise to EBITDA i36.2815.21
Risk & Other Metrics
Beta i0.041.23
Book Value per Share (MRQ) i₹115.19₹54.44

Financial Statements Comparison: GlaxoSmithKline vs Marksans Pharma

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)GLAXOMARKSANS
Revenue/Sales i₹8.05B₹6.20B
Cost of Goods Sold i₹2.88B₹2.62B
Gross Profit i₹5.17B₹3.58B
Research & Development iN/AN/A
Operating Income (EBIT) i₹2.36B₹770.22M
EBITDA i₹2.95B₹1.06B
Pre-Tax Income i₹2.79B₹765.98M
Income Tax i₹739.70M₹183.96M
Net Income (Profit) i₹2.05B₹582.02M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)GLAXOMARKSANS
Cash & Equivalents i₹5.39B₹4.96B
Total Current Assets i₹34.10B₹22.04B
Total Current Liabilities i₹19.05B₹4.77B
Long-Term Debt i₹24.92M₹2.63B
Total Shareholders Equity i₹19.51B₹24.89B
Retained Earnings i₹10.59B₹14.22B
Property, Plant & Equipment i₹2.70B₹185.74M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)GLAXOMARKSANS
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricGLAXOMARKSANS
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i97,6021,010,590
Average Daily Volume (90 Day) i94,9031,079,284
Shares Outstanding i169.41M453.16M
Float Shares i41.29M214.46M
% Held by Insiders i0.76%0.46%
% Held by Institutions i0.09%0.17%

Dividend Analysis & Yield Comparison: GlaxoSmithKline vs Marksans Pharma

MetricGLAXOMARKSANS
Last 12-Month Dividend i₹54.00₹1.40
Last 12-Month Dividend Yield i1.65%0.62%
3-Year Avg Annual Dividend i₹59.33₹0.72
3-Year Avg Dividend Yield i1.86%0.40%
3-Year Total Dividends i₹178.00₹2.15
Ex-Dividend DateMay 30, 2025Aug 01, 2025